for a number of reasons, such as keeping FT Sites reliable and secure,
personalising content and ads, providing social media features and to
analyse how our Sites are used.
A new world is possible.
Let's not go back to what wasn't working anyway.
Add this topic to your myFT Digest for news straight to your inbox
Companies had been backed by the government’s Covid Future Fund, through which loans converted into equity
Group behind AstraZeneca jab believes it has better chance of success in tackling tumours
Company that owns tech behind Oxford/AstraZeneca Covid vaccine raised $111m
New York listing would value Oxford-based Vaccitech at $613m, 44% higher than last month
Oxford university spinout behind AstraZeneca Covid-19 jab pushes ahead with US listing
Investors are increasingly frustrated with reputational damage and claims on management’s time
Vaccitech IPO likely to be seen as a loss for London as UK seeks to be hub for life sciences investment
Support scheme expected to leave British state invested in wide variety of businesses